We believe that this contemporary subset analysis of younger men enrolled in the screening group of the PLCO Cancer Screening Trial strengthens the merits of early baseline PSA level screening.29,30 Longer follow-up of the PLCO Cancer Screening Trial to 20 years, expected in 2022, will hopefully provide much-anticipated PCa-specific mortality data associated with baseline PSA testing. The gene discussed is KLK3; the disease is cancer.